Wang H, Qu X, De Plaen I G, Hsueh W
Department of Pathology, Children's Memorial Medical Center, Northwestern University Medical School, Chicago, Illinois, IL 60614, USA.
Br J Pharmacol. 2001 Jul;133(5):713-21. doi: 10.1038/sj.bjp.0704102.
The transcription factor family CCAAT/enhancer binding proteins (C/EBP) is involved in inflammation via the regulation of the gene expression of various pro-inflammatory cytokines and proteins. PAF and endotoxin (lipopolysaccharide, LPS) are known agents causing intestinal inflammation and injury. In this study, we examined the binding activity of C/EBP isoforms in rat small intestine in response to PAF (1.5 microg kg(-1), i.v.) or LPS (5 mg kg(-1), i.v.). We found that C/EBP is constitutively active in normal small intestine, mainly as C/EBP-alpha and beta (C/EBP-beta>alpha). Both C/EBP-alpha and beta are localized in the intestinal epithelial cells: C/EBP-alpha mainly in the crypts, and C/EBP-beta in both villi and crypts, as well as in some lamina propria cells. Only minute amounts of C/EBP-delta were found. PAF rapidly upregulates the binding activity of C/EBP-alpha and beta within 30 min. The increase in C/EBP-alpha is prominent in the crypt cells, whereas the change of C/EBP-beta is more widespread. LPS also increases the binding activity of C/EBP-alpha and beta, and the response is slower than PAF. PAF synergizes with LPS to markedly activate all three subunits. The increase in C/EBP-alpha is transient, whereas the other two have a sustained elevation until 120 min. After challenge with PAF (but not LPS), small amounts of nuclear factor -kappaB (NF-kappaB) p50 and p65 subunits are found in the C/EBP-DNA binding complex, indicating cross-dimerization of the two transcription families. Pretreatment of rats with pyrrolidine dithiocarbamate (PDTC) suppresses LPS-, but not PAF-, induced NF-kappaB and C/EBP binding activity, and significantly increases the C/EBP-delta subunit in LPS- or PAF-induced C/EBP complex. These results suggest that PAF and LPS activate intestinal C/EBP in vivo, probably via different pathways.
转录因子家族CCAAT/增强子结合蛋白(C/EBP)通过调控多种促炎细胞因子和蛋白质的基因表达参与炎症反应。血小板活化因子(PAF)和内毒素(脂多糖,LPS)是已知的引起肠道炎症和损伤的介质。在本研究中,我们检测了大鼠小肠中C/EBP亚型对PAF(1.5μg kg⁻¹,静脉注射)或LPS(5mg kg⁻¹,静脉注射)的反应性结合活性。我们发现C/EBP在正常小肠中具有组成性活性,主要以C/EBP-α和β(C/EBP-β>α)的形式存在。C/EBP-α和β均定位于肠上皮细胞:C/EBP-α主要位于隐窝,C/EBP-β位于绒毛和隐窝以及一些固有层细胞中。仅发现微量的C/EBP-δ。PAF在30分钟内迅速上调C/EBP-α和β的结合活性。C/EBP-α的增加在隐窝细胞中尤为明显,而C/EBP-β的变化更为广泛。LPS也增加C/EBP-α和β的结合活性,且反应比PAF慢。PAF与LPS协同作用以显著激活所有三个亚基。C/EBP-α的增加是短暂的,而其他两个亚基则持续升高直至120分钟。在用PAF(而非LPS)刺激后,在C/EBP-DNA结合复合物中发现少量核因子-κB(NF-κB)p50和p65亚基,表明这两个转录家族发生了交叉二聚化。用吡咯烷二硫代氨基甲酸盐(PDTC)预处理大鼠可抑制LPS诱导的而非PAF诱导的NF-κB和C/EBP结合活性,并显著增加LPS或PAF诱导的C/EBP复合物中的C/EBP-δ亚基。这些结果表明,PAF和LPS可能通过不同途径在体内激活肠道C/EBP。